Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周新低，触及$0.36。这一显著下跌反映了公司正经历艰难时期，过去一年股价暴跌了-84.39%。根据 InvestingPro 数据，公司市值已萎缩至仅220万美元，而在过去十二个月中录得负EBITDA为-1205万美元。投资者一直密切关注公司表现，这一新低点标志着对其未来前景和市 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

Processa Pharmaceuticals Inc. (PCSA) shares have tumbled to a 52-week low, touching down at $0.8, marking a significant downturn for the micro-cap company currently valued at just $2.68 million.

Investing.com - Processa Pharmaceuticals (NASDAQ: PCSA) reported first quarter EPS of $-0.810, $0.49 worse than the analyst estimate of $-0.320. Revenue for the quarter came in at... ByInvesting ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a ...

Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75 ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs ...

Financial Health for Processa Pharmaceuticals is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.